AtriCure, a leading innovator in treatments for atrial fibrillation, agreed to acquire SentreHEART, a privately held developer of percutaneous left atrial appendage management solutions, for $300m. “We believe that SentreHEART is a strategic addition to AtriCure, significantly expanding our addressable markets with a product designed for electrophysiologists,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “With our pursuit of labeling based on the aMAZE Trial, we are deepening our commitment to provide the broadest possible offering of ablation and left atrial appendage management solutions to our customers and their patients.”